Ethan S. Sokol

5.3k total citations · 1 hit paper
103 papers, 2.7k citations indexed

About

Ethan S. Sokol is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Ethan S. Sokol has authored 103 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 45 papers in Cancer Research and 40 papers in Molecular Biology. Recurrent topics in Ethan S. Sokol's work include Cancer Genomics and Diagnostics (43 papers), Cancer Immunotherapy and Biomarkers (13 papers) and PARP inhibition in cancer therapy (11 papers). Ethan S. Sokol is often cited by papers focused on Cancer Genomics and Diagnostics (43 papers), Cancer Immunotherapy and Biomarkers (13 papers) and PARP inhibition in cancer therapy (11 papers). Ethan S. Sokol collaborates with scholars based in United States, Italy and Germany. Ethan S. Sokol's co-authors include Piyush B. Gupta, Garrett M. Frampton, Dexter X. Jin, Yuxiong Feng, Ferenc Reinhardt, Siraj M. Ali, Alexa B. Schrock, Samuel J. Klempner, Jeffrey S. Ross and Razelle Kurzrock and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Ethan S. Sokol

96 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

2019 441 citations Alexa B. Schrock, Ethan S. Sokol et al. profile →

Peers

Ethan S. Sokol

ONCOL

PRM

PFM

Rebecca Senetta Italy

Simone Reu Germany

Ralph M. Wirtz Germany

Cristina E. Tognon United States

Eva Karamitopoulou Switzerland

Gregor Krings United States

Vassiliki Kotoula Greece

Douglas I. Lin United States

Yan‐Gao Man United States

Thomas Botton France

Rebecca Senetta Italy

Ethan S. Sokol

1.1k ×0.7

ONCOL

717 ×0.7

601 ×0.8

308 ×0.5

PRM

427 ×1.0

PFM

Citations per year, relative to Ethan S. Sokol Ethan S. Sokol (= 1×) peers Rebecca Senetta

Countries citing papers authored by Ethan S. Sokol

Since Specialization

Citations

This map shows the geographic impact of Ethan S. Sokol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ethan S. Sokol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ethan S. Sokol more than expected).

Fields of papers citing papers by Ethan S. Sokol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ethan S. Sokol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ethan S. Sokol. The network helps show where Ethan S. Sokol may publish in the future.

Co-authorship network of co-authors of Ethan S. Sokol

This figure shows the co-authorship network connecting the top 25 collaborators of Ethan S. Sokol. A scholar is included among the top collaborators of Ethan S. Sokol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ethan S. Sokol. Ethan S. Sokol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Riviere, Paul, et al.. (2024). Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies. Therapeutic Advances in Medical Oncology. 16. 12717789–12717789. 1 indexed citations

Kumar, Prashanth Ashok, et al.. (2024). Abstract PO5-06-14: Genomic Landscape and Clinical Outcomes of Triple-Negative Invasive Lobular Carcinoma. Cancer Research. 84(9_Supplement). PO5–6.

Sokol, Ethan S., et al.. (2024). Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors. SHILAP Revista de lepidopterología. 2(1). 77–77. 1 indexed citations

Rosenberger, Laura H., Richard F. Riedel, Emilia J. Diego, et al.. (2024). Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities. The Oncologist. 29(12). 1024–1031. 9 indexed citations

Posada, Jessica M., Evgeny Yakirevich, Ashish M. Kamat, et al.. (2024). Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2. Modern Pathology. 37(3). 100424–100424. 8 indexed citations

Moore, Jay A., Russell W. Madison, Justin Y. Newberg, et al.. (2023). Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response. JCO Precision Oncology. 7(7). e2300093–e2300093. 13 indexed citations

Batalini, Felipe, Russell W. Madison, Ethan S. Sokol, et al.. (2023). Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature. JCO Precision Oncology. 7(7). e2300091–e2300091. 8 indexed citations

Mezquita, Laura, Zhenzhan Kuang, Smruthy Sivakumar, et al.. (2023). MA14.08 Pathogenic Germline Variants in Patients with Non-Small Cell Lung Cancer (NSCLC) Detected by Tissue Comprehensive Genomic Profiling. Journal of Thoracic Oncology. 18(11). S151–S151. 2 indexed citations

Westphalen, C. Benedikt, Chantal Pauli, Nasséra Chalabi, et al.. (2023). Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study. ESMO Open. 8(6). 102035–102035. 7 indexed citations

10.

Williams, Erik A., Radwa Sharaf, Brennan Decker, et al.. (2020). CDKN2C -Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53 / RB1 –Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion. JCO Precision Oncology. 4(4). 955–971. 10 indexed citations

11.

Williams, Erik A., Meagan Montesion, Radwa Sharaf, et al.. (2020). CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma. Modern Pathology. 33(12). 2614–2625. 9 indexed citations

12.

Goodman, Aaron M., Andrea Castro, Rachel Marty Pyke, et al.. (2020). MHC-I genotype and tumor mutational burden predict response to immunotherapy. Genome Medicine. 12(1). 45–45. 79 indexed citations

13.

Goodman, Aaron M., Ethan S. Sokol, Garrett M. Frampton, Scott M. Lippman, & Razelle Kurzrock. (2019). Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunology Research. 7(10). 1570–1573. 202 indexed citations

14.

Moore, Heather M., Heidi Savage, Carol O’Brien, et al.. (2019). Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models. Molecular Cancer Therapeutics. 19(1). 292–303. 8 indexed citations

15.

Klempner, Samuel J., David Fabrizio, Shalmali Bane, et al.. (2019). Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. The Oncologist. 25(1). e147–e159. 243 indexed citations

16.

Knepper, Todd C., Meagan Montesion, Jeffery S. Russell, et al.. (2019). The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research. 25(19). 5961–5971. 111 indexed citations

17.

Levine, Kevin M., Nolan Priedigkeit, Ahmed Basudan, et al.. (2019). FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. npj Breast Cancer. 5(1). 19–19. 41 indexed citations

18.

Yuan, Wenlin, Leonard D. Goldstein, Steffen Durinck, et al.. (2019). S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis. Breast Cancer Research. 21(1). 152–152. 9 indexed citations

19.

Basudan, Ahmed, Nolan Priedigkeit, Ryan J. Hartmaier, et al.. (2018). Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. Molecular Cancer Research. 17(2). 457–468. 24 indexed citations

20.

Feng, Yuxiong, Ethan S. Sokol, Catherine Del Vecchio Fitz, et al.. (2014). Epithelial-to-Mesenchymal Transition Activates PERK–eIF2α and Sensitizes Cells to Endoplasmic Reticulum Stress. Cancer Discovery. 4(6). 702–715. 240 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact